Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalating-dose alteplase in acute lung injury, ARDS, or severe pneumonia
2010-024377-40Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tissue-plasminogen activator in acute lung injury (ALI), acute respiratory distress syndrome (ARDS) and pneumonia (2 arms), sponsored by Medical University of Vienna. Primary endpoint: PaO2/FiO2 ratio area under the curve. Started May 2011; status: terminated.
02
Drugs
tissue-plasminogen activator
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)pneumonia
Beyond the preview
Go deeper on 2010-024377-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024377-40.